<DOC>
	<DOCNO>NCT02103478</DOCNO>
	<brief_summary>This 2-stage , open-label study evaluate safety pharmacokinetics ASTX727 , well determine dose study 's second stage . In second stage select dose confirm evaluated clinical activity , include response rate .</brief_summary>
	<brief_title>Pharmacokinetic Guided Dose Escalation Dose Confirmation With Oral Decitabine Oral CDAi Patients With MDS</brief_title>
	<detailed_description>Dose level study 's second stage base safety pharmacokinetics .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>IPSS low , intermediate 1 , intermediate2 , high risk MDS ( include CMML ) Dose Escalation Dose ConfirmationRandomization ; intermediate2 , high risk MDS Dose ConfirmationOpen Label ECOG 0 2 No major surgery within 2 week start study treatment No cytotoxic chemotherapy within 2 week start study treatment Able swallow pill Previous treatment 2 course decitabine ( stage ) azacitidine ( Dose Confirmation stage ) Treatment investigational therapy within 2 week study treatment Uncontrolled medical disease ( ) active , uncontrolled infection Diagnosed AML Active uncontrolled gastric duodenal ulcer Known history HIV hepatitis C B</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>MDS</keyword>
</DOC>